LBPMedicine(SH:688393) Xin Lang Cai Jing·2026-01-30 07:45Core Viewpoint - The company anticipates a significant decline in net profit for the fiscal year 2025, projecting a loss between 52 million to 42 million yuan, representing a year-on-year decrease of 344.23% to 297.26% [1] Financial Performance - The expected non-recurring net profit is projected to be between -72 million to -62 million yuan, indicating a year-on-year decrease of 605.13% to 534.97% [1] - The decline in revenue and gross profit from the HPV product line is estimated to be approximately 46.5 million yuan and 46 million yuan, respectively [1] Operational Factors - The decrease in financial performance is attributed to the national centralized procurement policy affecting the HPV product line [1] - Business structure optimization and channel strategy adjustments have negatively impacted the current gross profit [1] - Increased research and development investments have led to a rise in costs [1] - The company has made provisions for asset impairment [1] Non-Recurring Gains - There has been an increase in investment income from associated companies, contributing positively to non-recurring gains [1]